Philips launched a new CT simulation workstation at the 2003 annual meeting of the American Association of Physicists in Medicine held Aug. 10 to 14 in San Diego. The AcQSim3 combines simulation features of the AcQSim workstation with Philips' radiation
Philips launched a new CT simulation workstation at the 2003 annual meeting of the American Association of Physicists in Medicine held Aug. 10 to 14 in San Diego. The AcQSim3 combines simulation features of the AcQSim workstation with Philips' radiation therapy planning (RTP) system Pinnacle3, creating a single shared platform and integrated workflow. Integration of the CT simulation workstation and RTP enables access to shared patient data from other Philips oncology workstations. The new AcQSim3 connects seamlessly to the company's image fusion application, Syntegra, and intensity-modulated radiation therapy application, P3IMRT. It is compatible with Philips' multimodality imaging systems, including the AcQSim CT, Gemini PET/CT, and Panorama MRI, as well as with other vendors' DICOM-compliant imaging systems. AcQSim3 can also communicate with other vendors' RTP systems via standard DICOM and DICOM-RT transfer protocols.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.
Emerging MRI Scoring System May Help Predict Recurrent and Metastatic Hepatocellular Carcinoma
February 12th 2025Preoperative use of the scoring system for gadoxetic acid-enhanced MRI demonstrated an average AUC of 85 percent and average specificity of 89 percent in external validation cohorts for pathologic features of hepatocellular carcinoma.
Key Chest CT Parameters for Body Composition May be Prognostic for Patients with Resectable NSCLC
February 11th 2025A high intermuscular adipose index has a 49 percent increased likelihood of being associated with lower overall survival in patients with resectable non-small cell lung cancer (NSCLC), according to new research.